A promising candidate for molecular targeting strategies focusing on the TME is vascular endothelial growth factor-A (VEGF) and its receptor VEGFR2 for use on tumor-associated endothelial cells that together have a key role in tumor neovascularization. Here, KDR is linked to neoplasm.